Date:8/17/2010

tal current assets 73,050,239 64,390,196 Property and equipment, net 13,928,075 13,204,825 Commercial leasing assets, net 36,542,390 36,710,934 Land use rights, net 4,969,850 4,988,817 Long term investment -- 888,960 $128,490,554 $120,183,732 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Short-term bank loans $32,839,062 $27,195,342 Accounts payable 7,718,548 6,175,266 Notes payable 48,756,300 50,020,476 Advance from customers 859,420 127,419 Due to related party- current portion 467,251 2,979,171 Income tax payable 5,543,077 5,277,239 Other payables 3,192,663 2,900,942 Loan from employees 1,507,404 1,476,292 Total current liabilities 100,883,725 96,152,147 Due to related party- long-term portion 2,000,254 1,986,114 Total Liabilities 102,883,979 98,138,261 COMMITMENTS AND CONTINGENCIES Stockholders' equity: Common stock ($.001 par value; 50,000,000 shares authorized, 26,000,000 shares issued and outstanding as of March 31, 2010 and December 31, 2009) 26,000 26,000 Additional paid-in capital 2,908,171 2,908,171 Statutory reserve 1,369,652 1,369,652 Retained earnings 19,535,677 16,179,230 Accumulated other comprehensive income 1,516,597 1,347,371 Total Equity of China Ruitai Shareholders 25,356,097 21,830,424 Equity attributable to noncontrolling interests 250,478 215,047 Total Stockholders' Equity 25,606,575 22,045,471 $128,490,554 $120,183,732 CHINA RUITAI INTERNATIONAL HOLDINGS CO., LTD. AND SUBSIDIARIES Consolidated Statements of Income and Comprehensive Income Three months ended Six months ended June 30, June 30, 2010 2009 2010 2009 (unaudited) (unaudited) (unaudited) (unaudited) Sales $11,171,175 $8,463,783 $21,409,431 $16,694,963 Cost of sales 8,222,567 5,506,063 15,152,439 10,482,604 Gross margin 2,948,608 2,957,720 6,256,992 6,212,359 Operating expenses: General and administrative expenses 215,858 683,737 500,110 1,498,970 Selling expenses 530,310 444,994 889,385 733,971 Total operating expense 746,168 1,128,731 1,389,495 2,232,941 Income from ope
'/>"/>

SOURCE China Ruitai International Holdings Co., Ltd. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth